Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats.
Pressure-overload left ventricular hypertrophy (LVH) is characterized by an increase in myocyte size and fibrosis. However, it is not clear how each of these components affects hypertensive heart disease (HHD). We have shown in 2 different rat models of hypertension that cardiac fibrosis can be reduced with N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), an antifibrotic peptide normally present in mammals. To assess how inhibition of fibrosis affects HHD, spontaneously hypertensive rats (SHR) and normotensive controls (WKY) were treated with Ac-SDKP or vehicle. Cardiac systolic and diastolic function were assessed using in vivo pressure-volume (PV) analysis. Left ventricle passive compliance was also determined ex vivo. We found that in SHR, Ac-SDKP normalized left ventricle total collagen content and interstitial collagen fraction without changing myocyte diameter or left ventricle mass. In WKY, collagen did not change significantly after treatment. Ac-SDKP did not affect left ventricle diastolic function, determined in vivo and ex vivo in SHR and WKY, whereas systolic function was significantly decreased in SHR treated with Ac-SDKP and unchanged in treated WKY. We concluded that in adult SHR, reducing left ventricle collagen deposition with Ac-SDKP does not improve diastolic function, whereas it decreases systolic performance. These findings suggest that total left ventricle collagen reduction per se does not necessarily benefit cardiac function. In HHD, other factors besides collagen quantity, such as myocyte hypertrophy and/or collagen type or cross-link, might be targeted to improve cardiac function.
Cingolani
Oscar H
OH
Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Health System, Detroit, Mich, USA.
Yang
Xiao-Ping
XP
Liu
Yun-He
YH
Villanueva
Mirko
M
Rhaleb
Nour-Eddine
NE
Carretero
Oscar A
OA
D000818:Animals; D002196:Capillaries / Q000473:pathology; D048429:Cell Size; D003094:Collagen / Q000378:metabolism; D003971:Diastole; D005355:Fibrosis; D006352:Heart Ventricles / Q000737:chemistry / Q000473:pathology; D006909:Hydroxyproline / Q000032:analysis; D006973:Hypertension / Q000150:complications* / Q000503:physiopathology; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D009842:Oligopeptides / Q000494:pharmacology / Q000627:therapeutic use*; D011312:Pressure; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013599:Systole / Q000502:physiology*
D009842:Oligopeptides; D003094:Collagen; C058504:goralatide; D006909:Hydroxyproline